Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFICACY AND TOLERABILITY OF AMITRIPTYLINOXIDE IN THE TREATMENT OF CHRONIC TENSION-TYPE HEADACHE - A MULTICENTER CONTROLLED-STUDY
Autore:
PFAFFENRATH V; DIENER HC; ISLER H; MEYER C; SCHOLZ E; TANERI Z; WESSELY P; ZAISERKASCHEL H; HAASE W; FISCHER W;
Indirizzi:
LEOPOLDSTR 59-II D-80802 MUNICH GERMANY UNIV ESSEN GESAMTHSCH,DEPT NEUROL W-4300 ESSEN 1 GERMANY UNIV ZURICH,DEPT NEUROL CH-8006 ZURICH SWITZERLAND UNIV VIENNA,DEPT NEUROL A-1010 VIENNA AUSTRIA INST NUMER STAT COLOGNE GERMANY
Titolo Testata:
Cephalalgia
fascicolo: 2, volume: 14, anno: 1994,
pagine: 149 - 155
SICI:
0333-1024(1994)14:2<149:EATOAI>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRICYCLIC ANTI-DEPRESSANTS; DOUBLE-BLIND; DRUGS;
Keywords:
AMITRIPTYLINE; AMITRIPTYLINOXIDE; CHRONIC TENSION-TYPE HEADACHE; DEPRESSION; MULTICENTER PLACEBO-CONTROLLED DOUBLE-BLIND STUDY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
V. Pfaffenrath et al., "EFFICACY AND TOLERABILITY OF AMITRIPTYLINOXIDE IN THE TREATMENT OF CHRONIC TENSION-TYPE HEADACHE - A MULTICENTER CONTROLLED-STUDY", Cephalalgia, 14(2), 1994, pp. 149-155

Abstract

Amitriptyline is the medication of first choice in the treatment of chronic tension-type headache. In 197 patients with chronic tension-type headache (87M and 110F with a mean age of 38 +/- 13 (18-68)) efficacy and tolerability of 60-90 mg amitriptylinoxide (AO) were compared with 50-75 mg amitriptyline (AM) and placebo (PL) in a double-blind, parallel-group trial consisting of a four weeks' baseline phase and 12 weeks of treatment. The primary study endpoint was a reduction of at least .50% of the product of headache duration and frequency and a reduction of at least 50% in headache intensity. Statistics used were Fisher's exact test and analysis of variance. No significant difference emerged between AO, AM and PL with respect to the primary study endpoint. Treatment response occurred in 30.3% of the AO, 22.4% of the AM and 21.9% of the PL group. A reduction in headache duration and frequency ofat least 50% was found in 39.4% on AO, in 25.4% on AM and in 26.6% onPL (p(AO-PL) = .1384, p(AM-FL) = 1-000, p(AO-AM) = .0973). A reduction in headache intensity of at least 50% was found in 31.8% on AO, in 26.9% on AM and in 26.6% on PL (p(AO-PL) = .5657, p(AM-PL) = 1.000, p(AO-AM) = .5715). Trend analysis with respect to a significant reductionof headache intensity (p < 0.05) and the product of headache durationand frequency revealed a superior effect of AO. Adverse events occurred in 75.8% on AO, 82.1% on AM and 76.6% on PL (p(AO-PL) = 1.000, P(AM-PL) = .5188, p(AO-AM) = .4017). Neither depressive symptoms, measuredby the SCL-90-R, nor study drug-related adverse events had any influence on the results.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 02:04:31